Clinical and Anthropometric Evolution of People Living with Human Immunodeficiency Virus during 6 Months of Dolutegravir Treatment in Kinshasa, Democratic Republic of Congo
Background: AntiRetroViral Treatment (ART) remains an important tool for reducing morbidity and mortality and improving the quality of life of people living with the Human Immunodeficiency Virus (PLHIV). Under the pressure of ART, several parameters of PLHIV change and are the subject of different evaluations. Objective: The objective of this work was to study the clinical and anthropometric evolution of PLHIV after 6 months of ART based on Dolutegravir (DTG). Methods: The present study was a non-interventional prospective cohort to assess the clinical and anthropometric evolution of PLHIV after 6 months of ART in the Ambulatory Treatment Center (CTA) for HIV in Kinshasa. The patients included were followed for 6 months in compliance with the schedule promulgated by the National Program. The parameters of interest were: Age, Sex, Marital Status, Weight, Height, Body Mass Index and Clinical Status. Results: On inclusion, 119 patients (56.3% women; 43.7% men) were selected. During the consultation appointments, 42 patients (66.7% women; 33.3% men) were present at M1, 37 patients (70.3% women; 29.7% men) at M3, and 67 patients (61.3% women and 38.7% men) in M6. On inclusion, 41.5% of patients were at Stage 3 and 47.0% had a normal clinical condition. In M1, 48.7% of patients were at Stage 1 and 65.8% had a normal clinical condition. At M3, 41.7% of patients were at Stage 3 and 67.6% had a normal clinical condition. At M6, 61.8% of patients were at Stage 3 and 67.9% had a normal clinical condition. On D0, 45.5% of patients were in the 45 to 55 kg range and 56.5% had a normal Body Mass Index (BMI). At M1, 45.7% were in the 45 to 55 kg range and 50.0% had a normal BMI. At M3, 34.4% were in the 45 to 55 kg range and 64.3% had a normal BMI. At M6, 31.8% were in the range of 45 to 55 kg and, respectively, 37.5% of patients were lean and had a normal BMI. Conclusion: The clinical and anthropometric parameters evolve in saw tooth. Improvements are easily visible up to the third month of AntiRetroViral Treatment (ART). At the sixth month, with the pressure of the infection by the Human Immunodeficiency Virus (HIV), the evolution of the patients is compromised.
References
[1]
ONUSIDA: Dernière statistique sur l’état de l’épidémie SIDA-UNAIDS.
[2]
UNAIDS, PNMLS: Baromètre analytique de la lutte contre le VIH/SIDA en République Démocratique Du Congo, progrès dans la réalisation des objectifs 95-95-95; 2021. Page 24-33.
[3]
Van Leth, F., Phanuphak, P., Stroes, E., Gazzard, B. and Cahn, P. (2004) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-TherapyNaive Patients Infected with HIV-1. PLOS Medicine, 1, e19. https://doi.org/10.1371/journal.pmed.0010019
[4]
Castebo, K. (2006) Nutrition et infection par le VIH en Afrique: Synthèse des connaissances vue par l’OMS. Transcriptase, 127, 8-11.
[5]
Macallan, D.C., Margaret, A., Nurlan, M.C., Milne, E., Graham, C.A. and Garlick, P.J. (1995) Whole-Body Protein Turnover from Leucine Kinetics and the Response to Nutrition in Human Immune Deficiency Virus Infection. The American Journal of Clinical Nutrition, 61, 818-826. https://doi.org/10.1093/ajcn/61.4.818
[6]
Haute Autorité de la santé (HAS) (2020) Dolutégravir/Lamivudine Dovato comprimé 50mg/30mg comprimé pelliculé, première évaluation. Variations du Poids corporel et les modifications de forme corporelle. https://www.catie.org
[7]
Tshingani, K., Mukumbi, H., Lubangi Muteba, M., Donnen, P. and Wilmet Dramaix, M. (2014) Profil comparatif et évolutif des personnes infectées par le Virus de l’Immunodéficience Humaine traitées aux ARV à Kinshasa, RD Congo. The Pan African Medical Journal, 19, Article No. 388.
[8]
Bulanda, B.I., Kateba, E.T., Bongenia, B.I., Kasongo, V.N., Kingombe, M.A. and Kamangu, E.N. (2018) Sociodemographic and Anthropometric Profile of Positive HIV Patients in Early Traditional Treatment: Case of the Bonkoko Center. Open Access Library Journal, 5, e4555. https://doi.org/10.4236/oalib.1104555
[9]
Losenga, L.O., Dikati, N.M., Bongenya, B.I., Ntumba, T.K., Booto, G.I., Dembo, R.D., et al. (2022) Sociodemographic and Anthropometric Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of the Congo. Open Access Library Journal, 9, e9056. https://doi.org/10.4236/oalib.1109056
[10]
Programme Nation de Lutte contre la VIH/SIDA et les ISTs, Ministère de la Santé Publique, République Démocratique du Congo (2016) Guide de prise en charge intégrée du VIH/SIDA en République Démocratique du Congo. Révision de Septembre.
[11]
Kamangu, N.E., Bwiri, B.B. and Mvumbi, L.G. (2019) Clinical and Paraclinical Profile of People Living with Human Immunodeficiency Virus on Second Line Treatment in Kinshasa, Democratic Republic of Congo. Open Access Library Journal, 6, e5499. https://doi.org/10.4236/oalib.1105499
[12]
Kamangu, N.E., Bulanda, I.B., Bongenia, I.B., Botomwito, T.H., Mvumbi, L.G., De Mol, P., et al. (2015) Virological Profile of Patients Infected with HIV Starting Antiretroviral Treatment in Kinshasa. Open Access Library Journal, 2, e1564. https://doi.org/10.4236/oalib.1101564
[13]
Desclaux, A. and Desgrées du Lou, A. (2006) Les Femmes Africaines face à l’épidémie du SIDA. Population et Sociétés, 428, 1-4. https://doi.org/10.3917/popsoc.428.0001
[14]
Karier, R. and Marissa, Y. (2009) Renforcement de l’intégration des services de planification familiale et de traitement du VIH. PRB USAID.
[15]
Programme conjoint des Nations Unies sur le VIH/SIDA (ONUSIDA) (2019) Les Communautés concernées: La Réponse au VIH en Afrique Occidentale et Centrale. Mise à Jour Mondiale sur le SIDA en 2019. https://www.unaids.org/sites/default/files/media_asset/2019_global-aids-report_western-and-central-africa_fr.pdf
[16]
Kamangu, N.E., Bulanda, B.I., Bongenya, B., Kateba, E.T., Okonda, M.O., Kasongo, V.N. and Kingombe, M.A. (2019) Evaluation of the Efficacy of the Phyto-Drug Djovikas: Traditional Treatment against HIV Infection. ARC Journal, 4, 1-4.
[17]
Booto, G.I., Selenge, S.M., Bongenya, B.I., Ntumba, T.K., Losenga, L.O., Dikati, N.M., et al. (2022) Clinical Profile of People Living with Human Immunodeficiency Virus Starting Treatment in Kinshasa, Democratic Republic of Congo. Open Access Library Journal, 9, e9134. https://doi.org/10.4236/oalib.1109134
[18]
Kamangu, N.E., Wumba, R.D.M., Situakibanza, H.N.T., Lukusa, P.T., Kapend, L.K., Mvumbi, G.L., Hayette, M.P. and Kalala, R.L. (2018) Molecular Epidemiology of Human Immunodeficiency Virus Type 1 and Therapeutic Monitoring of Patients Treated in Kinshasa/Democratic Republic of the Congo. International Journal of HIV and Aids Research, 2, 6-11.
[19]
Yeni, P. (2010) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d’experts. Médecine Sciences, Flammarion, Paris.
[20]
Kamangu, N.E. (2018) Estimation of Clinical, Immunological and Virological Failure of First Line Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo. Open Access Library Journal, 5, e4560. https://doi.org/10.4236/oalib.1104560
[21]
Kamanga, B.M., Kayembe, J.M.N., Nkiama, C.E., Kayembe, P.K., Kikontwe, L.K. and Nkoy, M.J.L. (2019) Valeurs spirométries de référence dans la population bantoue de Kinshasa de 20 à 70 ans. The Pan African Medical Journal, 33, Article No. 295. https://doi.org/10.11604/pamj.2019.33.295.16843
